Aclarion Secures Payer Coverage For Nociscan From Vitality, Now Covered By 3 Of The 4 Largest Private Health Insurers In The UK; Nearly 60% Of Private Health Insurance Patients In Greater London Now Have Access To Aclarion's Nociscan
Portfolio Pulse from Benzinga Newsdesk
Aclarion has secured payer coverage for its Nociscan technology from Vitality, making it now covered by three of the four largest private health insurers in the UK. This means nearly 60% of private health insurance patients in Greater London now have access to Nociscan.
August 13, 2024 | 1:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aclarion's Nociscan technology has gained coverage from Vitality, one of the largest private health insurers in the UK. This expands Nociscan's reach to nearly 60% of private health insurance patients in Greater London.
The coverage from Vitality significantly expands the market reach of Aclarion's Nociscan, potentially increasing its revenue and market penetration. This is a positive development for Aclarion.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
The expansion of Aclarion's Nociscan coverage to nearly 60% of private health insurance patients in Greater London could have a positive impact on the broader UK healthcare market, which is represented by the iShares MSCI United Kingdom ETF (EWU).
While the direct impact on EWU may be limited, the broader positive sentiment in the UK healthcare market due to Aclarion's expanded coverage could benefit the ETF.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 50